- Fusion Antibodies has started trading on AIM with a market capitalisation of £18.1m having raised £5.5m through a conditional placing of 6,707,317 new ordinary shares at 82p apiece.

The company said the proceeds would be used to fund the expansion of its existing laboratory space, increase its sales and marketing efforts, for the development of the new service lines, as well as providing additional working capital.

It said that in addition, £1.1m had been raised for selling shareholders.

At 8:13am: [LON:FAB] share price was +92.5p at 92.5p

Story provided by